Pramipexole-induced impulsivity in mildparkinsonian rats: a model of impulse control disorders in Parkinson's disease

Neurobiol Aging. 2019 Mar:75:126-135. doi: 10.1016/j.neurobiolaging.2018.11.021. Epub 2018 Nov 24.

Abstract

Treatment with dopaminergic agonists such as pramipexole (PPX) contributes to the development of impulse control disorders (ICDs) in patients with Parkinson's disease (PD). As such, animal models of abnormal impulse control in PD are needed to better study the pathophysiology of these behaviors. Thus, we investigated impulsivity and related behaviors using the 5-choice serial reaction time task, as well as FosB/ΔFosB expression, in rats with mild parkinsonism induced by viral-mediated substantia nigra overexpression of human A53T mutated α-synuclein, and following chronic PPX treatment (0.25 mg/kg/d) for 4 weeks. The bilateral loss of striatal dopamine transporters (64%) increased the premature response rate of these rats, indicating enhanced waiting impulsivity. This behavior persisted in the OFF state after the second week of PPX treatment and it was further exacerbated in the ON state throughout the treatment period. The enhanced rate of premature responses following dopaminergic denervation was positively correlated with the premature response rate following PPX treatment (both in the ON and OFF states). Moreover, the striatal dopaminergic deficit was negatively correlated with the premature response rate at all times (pretreatment, ON and OFF states) and it was positively correlated with the striatal FosB/ΔFosB expression. By contrast, PPX treatment was not associated with changes in compulsivity (perseverative responses rate). This model recapitulates some features of PD with ICD, namely the dopaminergic deficit of early PD and the impulsivity traits provoked by dopaminergic loss in association with PPX treatment, making this model a useful tool to study the pathophysiology of ICDs.

Keywords: 5-choice serial reaction time task; FosB/ΔFosB; Impulse control disorders; Parkinson's disease; Pramipexole; α-synuclein.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Corpus Striatum / metabolism
  • Disruptive, Impulse Control, and Conduct Disorders / physiopathology*
  • Dopamine / metabolism
  • Dopamine Agonists / pharmacology
  • Dopamine Plasma Membrane Transport Proteins / metabolism
  • Impulsive Behavior / drug effects*
  • Motor Activity / drug effects
  • Motor Activity / physiology
  • Parkinson Disease / metabolism
  • Parkinson Disease / physiopathology*
  • Parkinsonian Disorders / complications
  • Pramipexole / pharmacology*
  • Rats
  • Substantia Nigra / metabolism
  • Substantia Nigra / physiopathology

Substances

  • Dopamine Agonists
  • Dopamine Plasma Membrane Transport Proteins
  • Pramipexole
  • Dopamine